195 related articles for article (PubMed ID: 27362533)
1. Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
De Cock E; Kritikou P; Sandoval M; Tao S; Wiesner C; Carella AM; Ngoh C; Waterboer T
PLoS One; 2016; 11(6):e0157957. PubMed ID: 27362533
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
3. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
[TBL] [Abstract][Full Text] [Related]
4. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
[TBL] [Abstract][Full Text] [Related]
5. Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.
Drill E; Qiu A; Shapouri S; To TM; Ravelo A; Schade J; Dawson K; Matasar M
Oncology (Williston Park); 2021 Dec; 35(12):804-811. PubMed ID: 35089000
[TBL] [Abstract][Full Text] [Related]
6. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
[No Abstract] [Full Text] [Related]
7. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
[TBL] [Abstract][Full Text] [Related]
8. Update on the subcutaneous administration of rituximab in Canadian cancer centres.
Stewart D; Aucoin JS; Crosbie T; Forman M; Lye E; Christofides A; Mitha A
Curr Oncol; 2020 Apr; 27(2):113-116. PubMed ID: 32489254
[TBL] [Abstract][Full Text] [Related]
9. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
[TBL] [Abstract][Full Text] [Related]
10. Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
Slavcev M; Spinelli A; Absalon E; Masterson T; Heuck C; Lam A; De Cock E
Clinicoecon Outcomes Res; 2021; 13():465-473. PubMed ID: 34135605
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective.
Carlson J; Cox K; Bedwell K; Ku M
Int J Nurs Pract; 2015 Dec; 21 Suppl 3():1-13. PubMed ID: 26681664
[TBL] [Abstract][Full Text] [Related]
12. Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion.
Mihajlović J; Bax P; van Breugel E; Blommestein HM; Hoogendoorn M; Hospes W; Postma MJ
Clin Ther; 2017 Jun; 39(6):1221-1232.e4. PubMed ID: 28579210
[TBL] [Abstract][Full Text] [Related]
13. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
Harvey MJ; Zhong Y; Morris E; Beverage JN; Epstein RS; Chawla AJ
PLoS One; 2022; 17(1):e0261336. PubMed ID: 35073335
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites.
Stewart DA; Boudreault JS; Maturi B; Boras D; Foley R
Curr Oncol; 2018 Oct; 25(5):300-306. PubMed ID: 30464679
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.
Davies A; Berge C; Boehnke A; Dadabhoy A; Lugtenburg P; Rule S; Rummel M; McIntyre C; Smith R; Badoux X
Adv Ther; 2017 Oct; 34(10):2210-2231. PubMed ID: 28983819
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
[TBL] [Abstract][Full Text] [Related]
17. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
[TBL] [Abstract][Full Text] [Related]
18. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
Salar A; Avivi I; Bittner B; Bouabdallah R; Brewster M; Catalani O; Follows G; Haynes A; Hourcade-Potelleret F; Janikova A; Larouche JF; McIntyre C; Pedersen M; Pereira J; Sayyed P; Shpilberg O; Tumyan G
J Clin Oncol; 2014 Jun; 32(17):1782-91. PubMed ID: 24821885
[TBL] [Abstract][Full Text] [Related]
19. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.
North RT; Harvey VJ; Cox LC; Ryan SN
Clinicoecon Outcomes Res; 2015; 7():423-30. PubMed ID: 26251623
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
